Alan Lau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alan Lau has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Brian Lee
Division of Nephrology, Kaiser Permanente Hawaii, Moanalua Medical Center, 3288 Moanalua Rd, Honolulu, HI, 96819, USA
1 shared publication - Di Meng
Director of Analytics and Evaluation of the Health Information Technology Transformation & Analytics Department of Kaiser Permanente in Oakland, CA.
1 shared publication - Linda Radler
HIT Transformation/Analytics, Kaiser Permanente, 1800 Harrison, Oakland, CA, 94612, USA
1 shared publication - Marianne Turley
Resource Manager of Analytics for the Data Information Management Enhancement Department of Kaiser Permanente Northwest in Portland, OR.
1 shared publication - Terhilda Garrido
Vice President of Health Information Technology Transformation and Analytics in National Quality for Kaiser Permanente in Oakland, CA.
1 shared publication - Yi Yvonne Zhou
Northwest Permanente, Innovation and Care Transformation, Portland, Oregon, USA
1 shared publication
Latest Publications
- Open Access
- 15 August 2012
- Published by Springer Nature in BMC Health Services Research
- Vol. 12 (1) , 252
Effects of proactive population-based nephrologist oversight on progression of chronic kidney disease: a retrospective control analysis
Background: Benefits of early nephrology care are well-established, but as many as 40% of U.S. patients with end-stage renal disease (ESRD) do not see a nephrologist before its onset. Our objective was to evaluate the effect of proactive, population-based nephrologist oversight (PPNO) on chronic kidney disease (CKD) progression. Methods: Retrospective control analysis of Kaiser Permanente Hawaii members with CKD using propensity score matching methods. We matched 2,938 control and case pairs of individuals with stage 3a CKD for the pre-PPNO period (2001–2004) and post-PPNO period (2005–2008) that were similar in other characteristics: age, gender, and the presence of diabetes and hypertension. After three years, we classified the stage outcomes for all individuals. We assessed the PPNO effect across all stages of progression with a χ 2- test. We used the z-score test to assess the proportional differences in progression within a stage. Results: The progression within the post-PPNO period was less severe and significantly different from the pre-PPNO period (p = 0.027). Within the stages, there were 2.6% more individuals remaining in 3a in the post-period (95% confidence interval [CI], 1.5% to 3.8%; P value < 0.00001). Progression from 3a to 3b was 2.2% less in the post-period (95% [CI], 0.7% to 3.6%; P value = 0.0017), 3a to 4/5 was 0.2% less (95% CI, 0.0% to 0.87%; P value = 0.26), and 3a to ESRD was 0.24% less (95% CI, 0.0% to 0.66%, P value = 0.10). Conclusions: Proactive, population-based nephrologist oversight was associated with a statistically significant decrease in progression. With enabling health information technology, risk stratification and targeted intervention by collaborative primary and specialty care achieves population-level care improvements. This model may be applicable to other chronic conditions.
- 15 August 2012
- Published by Springer Nature in BMC Health Services Research
- Vol. 12 (1) , 252
Open AccessEffects of proactive population-based nephrologist oversight on progression of chronic kidney disease: a retrospective control analysis
Background: Benefits of early nephrology care are well-established, but as many as 40% of U.S. patients with end-stage renal disease (ESRD) do not see a nephrologist before its onset. Our objective was to evaluate the effect of proactive, population-based nephrologist oversight (PPNO) on chronic kidney disease (CKD) progression. Methods: Retrospective control analysis of Kaiser Permanente Hawaii members with CKD using propensity score matching methods. We matched 2,938 control and case pairs of individuals with stage 3a CKD for the pre-PPNO period (2001–2004) and post-PPNO period (2005–2008) that were similar in other characteristics: age, gender, and the presence of diabetes and hypertension. After three years, we classified the stage outcomes for all individuals. We assessed the PPNO effect across all stages of progression with a χ 2- test. We used the z-score test to assess the proportional differences in progression within a stage. Results: The progression within the post-PPNO period was less severe and significantly different from the pre-PPNO period (p = 0.027). Within the stages, there were 2.6% more individuals remaining in 3a in the post-period (95% confidence interval [CI], 1.5% to 3.8%; P value < 0.00001). Progression from 3a to 3b was 2.2% less in the post-period (95% [CI], 0.7% to 3.6%; P value = 0.0017), 3a to 4/5 was 0.2% less (95% CI, 0.0% to 0.87%; P value = 0.26), and 3a to ESRD was 0.24% less (95% CI, 0.0% to 0.66%, P value = 0.10). Conclusions: Proactive, population-based nephrologist oversight was associated with a statistically significant decrease in progression. With enabling health information technology, risk stratification and targeted intervention by collaborative primary and specialty care achieves population-level care improvements. This model may be applicable to other chronic conditions.